申请人:Kissei Pharmaceutical Co., Ltd.
公开号:US05624948A1
公开(公告)日:1997-04-29
1-(2-benzimidazolyl)-1,5-diazacyclooctane compounds represented by the formula: ##STR1## wherein X represents a hydrogen atom or a halogen atom; Y represents a covalent bond, a straight- or branched-chain alkylene group having 1 to 6 carbon atoms, or a straight- or branched-chain alkenylene group having 2 to 6 carbon atoms; R represents a hydrogen atom, or a straight- or branched-chain alkyl group having 1 to 6 carbon atoms; and pharmaceutically acceptable salts thereof. The compounds represented above are novel potent and long-lasting histamine HI-receptor antagonist with less-topical irritation, and can be topically administered by inhalation for the treatment of bronchial asthma.
1-(2-苯并咪唑基)-1,5-二氮杂环辛烷化合物的化学式如下:其中X代表氢原子或卤原子;Y代表共价键,具有1至6个碳原子的直链或支链烷基基团,或具有2至6个碳原子的直链或支链烯烃基团;R代表氢原子,或具有1至6个碳原子的直链或支链烷基基团;以及其药学上可接受的盐。上述化合物是新颖的高效长效组胺H1受体拮抗剂,具有较少局部刺激性,可通过吸入经皮途径治疗支气管哮喘。